1. Government business scaled back to focus on higher-margin products Delivered - In the September 2020 announcement, management committed to scaling back government business to focus on higher-margin, differentiated products and food supplements. Domestic revenue fell from ₹80.4 crore in FY24 to ₹53.6 crore in FY25 and ₹49.2 crore in FY26.
2. Deemed export business - maintain over 17% revenue run rate Missed - In the September 2020 announcement, management said deemed export would be maintained at a revenue run rate of over 17% depending on margins. FY26 deemed export was ₹10.3 crore, only \~2.8% of total revenue.
3. GCA - ₹30-40 crore against FY25 repayment obligations of ₹13.48 crore Delivered - In the April 2024 announcement, GCA was expected in the range of ₹30-40 crore against FY25 repayment obligations of ₹13.48 crore. FY25 EBITDA was ₹49.5 crore with finance cost of ₹11.4 crore, and no default was disclosed.
4. Debt-funded capex - phased over next two years Delivered - In the June 2023 announcement, ongoing debt-funded capex was planned in a phased manner over the next two years. Capex of ₹83.2 crore was incurred in FY24, ₹36.5 crore in FY25 and ₹40.9 crore in FY26, with debt rising from ₹59.6 crore to ₹123 crore.
5. Company growth - 25-30% in next 2-3 years On track - At the Q4 FY25 call, management affirmed company growth of "25%-30% in the next 2-3 years"; Q1 FY27 guidance set FY27 growth at 10-15% and FY28 at 30-35% conditional on EU-GMP. FY26 revenue declined 1.2%, but Q1 FY27 grew 31.2% YoY; the horizon through FY28 is open.
6. Base business growth - 5-10% for FY26 Missed - At the Q4 FY25 call, base business (ex-NIP/OTF) growth was expected at "5%-10%" for FY26. FY26 total revenue declined 1.2% to ₹374.4 crore; with NIP+OTF down from ₹62.4 crore to ₹47.9 crore, base business was \~₹326.5 crore, implying \~3% growth.
7. No major CapEx - only normal upgradation Delivered - At the Q4 FY25 call, management stated firmly that no further major CapEx was expected, only normal upgradation; Q1 FY27 confirmed only \~₹15-20 crores remaining for enzyme and Nutra plant upgrades. FY26 capex was ₹40.9 crore, consistent with upgradation rather than major projects.
8. Employee cost - stabilize around ₹65-68 crore for FY26 Missed - At the Q4 FY25 call, management confirmed employee cost expected to stabilize around ₹65 crore to ₹68 crore for FY26. FY26 costs were elevated by senior management onboarding, and Q1 FY27 run-rate of \~₹19 crore per quarter implies \~₹76 crore annualized.
9. Asset turnover - \~2.5x from installed capacity over 2-3 years On track - At the Q4 FY24 call, management confirmed \~2.5x asset turnover from installed capacity as the ideal number over the next 2-3 years. FY26 revenue of ₹374.4 crore against gross block of ₹386.2 crore implies \~0.97x; the horizon through FY27 is open.
10. Interest costs - not to rise further Missed - At the Q4 FY23 call, management said interest costs will not rise further and will be "in the similar line going forward", aided by better credit rating. Finance cost rose from ₹5.6 crore in FY23 to ₹6.9 crore in FY24, ₹11.4 crore in FY25 and ₹13.2 crore in FY26.
11. Debt reduction - on similar lines as FY23 Missed - At the Q4 FY23 call, management said debt reduction will be "on the similar lines" as FY23 depending on CapEx; later revisions saw debt peaking with repayment starting and borrowings to "remain constant". Borrowings instead rose from ₹59.6 crore in FY23 to ₹145.2 crore as of June 2026.
12. R&D spend - around 7% of revenue Delivered - At the Q4 FY24 call, R&D spending was guided at around 7% of total revenue for FY25, revised to \~8.5% at Q4 FY25 and \~8.3% at Q4 FY26. Actuals were 9.7% of TOI in FY24, 8.8% in FY25 and 8.3% in FY26, in line with the revised range.
13. NIP run-rate - maintain ₹16-18 crore per quarter minimum Missed - At the Q4 FY26 call, management committed to maintaining the NIP run-rate of \~₹16-18 crore per quarter as a minimum for ROW/Pharmerging markets. Q1 FY27 NIP revenue was ₹10.1 crore, below the minimum, after ₹15.5 crore in Q4 FY26.
14. FY27 EBITDA margin - mid-teen side On track - At the Q4 FY26 call, management guided margins to improve to "more on the mid teen side" for FY27, reiterated at Q1 FY27 as upper teens post EU-GMP. Q1 FY27 EBITDA margin was 3.7%; the full-year outcome is not yet available.
15. Nutraceutical business growth - 10-15% every year over 24 months On track - At the Q4 FY26 call, management guided nutraceutical growth of "about 10% to 15% growth happening every year" over the coming 24 months. FY26 nutraceutical revenue declined from \~₹95 crore to \~₹75 crore on the Middle East geopolitical crisis, but Q1 FY27 revenue of ₹26.8 crore was up 71% YoY.
16. 17 NIP+OTF products commercialization - within 24 months On track - At the Q4 FY26 call, management endorsed the view that all 17 NIP+OTF products will be commercialized within the next 24 months ("that's a fair view"). As of Q1 FY27, MAs for about 8 to 10 products are expected once EU-GMP comes through, with a 12-18 month outlook on the pipeline.
17. Gastro enzyme product scale - ₹1500 crore plus in FY28 Pending - At the Q4 FY26 call, management confirmed the plan to scale the gastro enzyme product to "1500 crore plus in FY28" ("That is the plan"). The enzyme MA was expected within a couple of months as of Q3 FY26, with FY28 the first full commercialization year; no FY28 outcome is available yet.
18. Pancreatin block - separate site with own accreditation by March 2027 On track - At the Q3 FY26 call, management committed to converting the pancreatin block into a separate site with its own accreditation "by March 27th" (FY27). A dedicated new block was built by Q4 FY26, with only \~₹15-20 crores of upgrade CapEx remaining, starting in Q2 FY27.
19. Debtor collection days - reduce from \~100 to \~80 days On track - At the Q1 FY27 call, management set a target to reduce debtor collection days from around 100 to around 80 to improve cash flows and working capital. Q1 FY27 debtors and inventory were on the higher side, with collections improving; no explicit confirmation of the 80-day level yet.
20. FY28 revenue growth - 30-35% conditional on EU-GMP Pending - At the Q1 FY27 call, management guided FY28 revenue growth of "about 30-35% growth easily", conditional on EU-GMP and supplies starting. At least 60-70% of the guided growth is attributed to EU-GMP; no FY28 outcome is available yet.
21. FY27 revenue growth - 10-15% even without EU-GMP On track - At the Q1 FY27 call, management guided FY27 revenue growth of 10-15% vs FY26 even if EU-GMP does not come in FY27. Q1 FY27 revenue was ₹94.2 crore, up 31.2% YoY; the full-year outcome is not yet available.
22. Tamsulosin + Dutasteride Australia supplies - within 3-4 months of site transfer On track - At the Q2 FY26 call, management guided supplies from the TGA-approved alternate site could start "after 3 months or 4 months hopefully", with sales between "Q4 of this year and Q1 of the next year". As of Q1 FY27, an Australian order was received with supplies to start "in the next two to three months"; supplies have not yet started.
23. NIP commercialization in regulated markets - calendar year 2026 Missed - At the Q1 FY26 call, NIP commercialization, excepting U.K., was expected in calendar year '26 after a 3 to 6 month shift; later revisions pushed EU sales to Q1/Q2 FY27 and then Q4 FY27. As of Q1 FY27 (August 2026), no regulated-market NIP commercialization has occurred, with EU-GMP recertification still pending.
24. EU-GMP reinstatement - within 6-9 months of CAPA submission Partial - At the Q1 FY26 call, management expected the CAPA plan complete within 6 to 9 months and a reinspection within 6 months; later revisions moved expectations to March 2026, June/July 2026 and Q2 FY27. The reinspection was conducted in May 2026, but recertification was still pending as of August 2026.
25. FY26 revenue - broadly in line with FY25 Delivered - At the Q2 FY26 call, management guided FY26 revenues "in the range of FY '25 revenues broadly in line with last year", reiterated as "we stick to it". FY26 total operating income was ₹374.4 crore, broadly in line with FY25's ₹379 crore, a 1.2% decline.
26. CWIP capitalization - most CWIP capitalized in March 2025 Missed - At the Q2 FY25 call, Zulfiquar Kamal said CWIP projects would be completed by year-end and "we hope to capitalize most of the CWIP in March 25". CWIP instead rose from ₹42.28 crore in FY24 to ₹70.46 crore in FY25 and ₹95.53 crore in FY26, indicating projects were not capitalized as guided.
27. Initial 10 NIP products - BE equivalence and dossier completion by year-end CY24 Partial - At the Q2 FY25 call, Zulfiquar Kamal said 10 NIP products' BE equivalence and dossier completion would be done "by this year end", with Zain Daud noting 6 developed and filed and full filings targeted by Q4 FY25 or Q1 FY26. By FY25, 8 of 12 NIP products were developed, with all 12 completed only by FY26.
28. FY25 EBITDA growth - around 14-15% with margin increase Missed - At the Q2 FY25 call, Zulfiquar Kamal guided "around 14% to 15% growth in EBITDA plus slight increase in the margin also over the last year". FY25 EBITDA was ₹49.5 crore, +6.4% from ₹46.5 crore in FY24, with margin improving to 13.1% from 12.7%.
29. FY25 revenue growth - around 10% over FY24 Missed - At the Q2 FY25 call, Zulfiquar Kamal guided FY25 revenue growth of "around 10% growth over the last year for the March '25 ending". FY25 total operating income was ₹379 crore, +3.2% YoY from ₹367.4 crore in FY24.
30. NIP+OTF revenue - ₹150-200 crore segment in 3-4 years On track - At the Q4 FY24 call, Anwar Daud endorsed an analyst's view that NIP+OTF could become a Rs. 150-200 crore revenue segment over the next 3 to 4 years ("That would probably be in the range of that"); at Q4 FY26 management declined to confirm a 250-300 crore peak assumption. FY25 NIP+OTF sales were ₹62.4 crore and FY26 ₹47.9 crore; the horizon through FY28 is open.
31. NIP+OTF contribution - 30-40% of overall business in 2-3 years On track - At the Q3 FY24 call, management said NIP+OTF could become 30-40% of overall business in the next two-three years ("Hopefully, yes"); later revisions saw 20-40% over time, "around 30%-40% in the coming years" and a 50:50 split projected. Contribution was 12% in FY24, 19% in FY25 and 13% in FY26; the horizon through FY27 is open.
32. Capacity expansion - double in next two years / 25-40% enhancement Partial - At the Q3 FY24 call, management guided that overall capacity would "actually double in the next two" years, with "around 25% to 40% enhancement in capacity in the coming couple of years". Capex of ₹83.2 crore in FY24, ₹36.5 crore in FY25 and ₹40.9 crore in FY26 took gross block from \~₹190 crore to \~₹340-odd crore, but utilization remained "very low" and no disclosure confirms the doubling.
33. FY24 revenue - repeat last year's performance Missed - At the Q2 FY24 call, management expected "we will be able to repeat the performance of last year" on revenue; at Q3 FY24 this was reset to falling short "by 10% to 15%". FY24 total operating income was ₹367.4 crore, down 7.8% YoY from ₹398.5 crore in FY23, within the revised shortfall range.
34. EBITDA margin improvement - 15% to 17% Missed - At the Q3 FY24 call, management guided EBITDA margin improvement to "15% to 17%"; later revisions pointed to "upper teens" going forward and once regulated-market business ramps up. Actual margins were 12.7% in FY24, 13.1% in FY25, 11.1% in FY26 and 3.7% in Q1 FY27.
35. Existing business growth - upper teen growth over 3-5 years Missed - At the Q4 FY23 call, management guided that RoW and existing business will grow at "upper teen" growth, with major future growth from NIP products in regulated markets; Q4 FY24 affirmed 15-20% base growth over 3-4 years ("Sure, that is how it will grow"). Revenue declined 7.8% in FY24, grew 3.2% in FY25 and declined 1.2% in FY26, with base business down from \~₹382 crore to \~₹317 crore.
36. Regulated market share of revenue mix - double to 15-20% in coming few years On track - At the Q4 FY23 call, management said the regulated market share of revenue mix will "double in the coming few years", confirming "Between 15% to 20%" of the total mix; later revisions pointed to 20-30% of TOI from NIP agreements and \~30% from regulated markets. NIP+OTF reached 16.5% of revenue in FY25 but fell to 13% in FY26, with EU-GMP suspension in July 2025 blocking regulated-market traction.
37. OTF/NIP-related revenue (Sildenafil, Rizatriptan) - start Q2 or Q3 FY24 Delivered - At the Q4 FY23 call, management said OTF/NIP-related revenue (Sildenafil, Rizatriptan) "may start in the second quarter or maximum by third quarter" of FY24. The first commercial sildenafil citrate 50 mg ODS order was supplied in Europe in Q2 FY24, and Rizatriptan saw MA transfer and packaging finalization in Q3 FY24.
38. EU approval for NIP products - within 18-24 months of FY23 submissions Delivered - At the Q4 FY23 call, management said EU approval for the two NIP products submitted in the last quarter of FY23 is expected "approximately within 18 months to 24 months". The Q4 FY25 deck discloses 2 EU Marketing Authorizations secured for NIP products - Dimethyl Fumarate and Azithromycin Oral Suspension - within that window, though the FY23 call did not name the two submitted products.
39. NIP revenue from manufacturing and sales - by end of 2024 Partial - At the Q4 FY23 call, management said NIP registrations take \~1.5 years, so revenues from manufacturing and sales were expected "by end of '24"; later revisions moved regulated-market business to H2 FY25. NIP manufacturing and sales revenue in FY24 was ₹24.1 crore, but it came from RoW/emerging markets, with EU MAs still pending at Q4 FY24.
40. NIP product registrations - \~10 EU submissions by end of FY24 Missed - At the Q4 FY23 call, management gave a filing plan of 2 EU submissions in Q1 FY24, 2 in Q2 FY24 and 3 in the last quarter - approximately 10 submissions "till the end of this financial year"; Q1 FY24 reaffirmed "still on track for the 4 filings this year". Actuals show 3 NIPs filed in FY24, totalling 5 EU filings to date.